Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Genome-wide CRISPRa screens identify modulators of CAR T survival across diverse tumor cytokine milieus.

Created on 25 Oct 2026

Authors

Benjamin C Curtis, Cailyn H Spurrell, Lindsay Flint, Aalton M Lande, Marissa Leonardi, James M Rosser, Tavie Parker, Tiffanie Chai, Ardizon Valdez, Ryma Toumi, Nat Murren, Michael Fitzgerald, Jasmin Martinez-Reyes, Finn Watt, Christopher P Saxby, Corinne Summers, Kamila S Gwiazda, Michael C V Jensen, Shannon K Oda

Published in

Molecular therapy. Nucleic acids. Volume 37. Issue 4. Pages 103117. Dec 08, 2026. Epub Sep 28, 2026.

Abstract

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of B cell malignancies, and extending this success to other cancers remains an urgent clinical objective. CRISPR activation (CRISPRa) is a gene nomination platform with the potential to direct next-generation cell product development, but genome-wide surveys using this technology in primary T cells have been limited by prohibitive cell requirements and short-lived activity. Here, we describe a CAR-restricted T cell expansion platform generating yields of CRISPRa-CAR T cells far exceeding those required for genome-scale screening (∼109). CRISPRa activity is sustained by incorporating divergent, duplicate elongation factor 1α core/human T cell leukemia virus hybrid promoters and by delivering guide RNAs late by lentiviral transduction to avoid losing perturbations that compromise early T cell activation or expansion. Manufactured CRISPRa-CAR T cells maintain potent on-target gene overexpression (>85% target+) across varied cell subsets, including those associated with T cell exhaustion, and over extended culture periods. When applied to survival-based genome-wide screens, CRISPRa-CAR T cell pools nominate endogenous genes that enhance CAR T cell persistence across varied cytokine levels in the presence of tumor (e.g., IRF4, GFI1, and GSE1). In a proof-of-concept study, we find that the survival effect of GSE1 can be preserved using a clinically relevant transgene overexpression strategy. More broadly, this screening framework establishes a foundation for systematic identification and downstream validation of genes that enhance cellular therapies.

PMID:
42927201
Bibliographic data and abstract were imported from PubMed on 25 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 21
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement